| Lactate buildup at the site of chronic inflammation promotes disease by inducing CD4+ T cell metabolic rewiring V Pucino, M Certo, V Bulusu, D Cucchi, K Goldmann, E Pontarini, R Haas, ... Cell metabolism 30 (6), 1055-1074. e8, 2019 | 410 | 2019 |
| Human liver-resident CD56bright/CD16neg NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways K Hudspeth, M Donadon, M Cimino, E Pontarini, P Tentorio, M Preti, ... Journal of autoimmunity 66, 40-50, 2016 | 255 | 2016 |
| BLyS upregulation in Sjögren’s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands L Quartuccio, S Salvin, M Fabris, M Maset, E Pontarini, M Isola, S De Vita Rheumatology 52 (2), 276-281, 2013 | 192 | 2013 |
| Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren’s syndrome with ectopic germinal centres and MALT lymphoma E Pontarini, WJ Murray-Brown, C Croia, D Lucchesi, J Conway, ... Annals of the rheumatic diseases 79 (12), 1588-1599, 2020 | 144 | 2020 |
| Lymphomas complicating primary Sjögren’s syndrome: from autoimmunity to lymphoma G Nocturne, E Pontarini, M Bombardieri, X Mariette Rheumatology 60 (8), 3513-3521, 2021 | 123 | 2021 |
| The role of natural killer cells in autoimmune liver disease: a comprehensive review K Hudspeth, E Pontarini, P Tentorio, M Cimino, M Donadon, G Torzilli, ... Journal of autoimmunity 46, 55-65, 2013 | 94 | 2013 |
| The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study L Quartuccio, M Fabris, E Pontarini, S Salvin, A Zabotti, M Benucci, ... Annals of the Rheumatic Diseases 73 (4), 716-721, 2014 | 78 | 2014 |
| Current views on the pathogenesis of Sjögren's syndrome E Pontarini, D Lucchesi, M Bombardieri Current opinion in rheumatology 30 (2), 215-221, 2018 | 71 | 2018 |
| Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren’s syndrome E Pontarini, M Fabris, L Quartuccio, M Cappeletti, F Calcaterra, A Roberto, ... Rheumatology 54 (8), 1429-1434, 2015 | 71 | 2015 |
| Role of oral cyclophosphamide in the treatment of giant cell arteritis L Quartuccio, M Maset, G De Maglio, E Pontarini, M Fabris, E Mansutti, ... Rheumatology 51 (9), 1677-1686, 2012 | 66 | 2012 |
| Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure S Arends, L de Wolff, JF van Nimwegen, GMPJ Verstappen, J Vehof, ... The Lancet Rheumatology 3 (8), e553-e562, 2021 | 65 | 2021 |
| One year in review 2020: pathogenesis of primary Sjögren’s syndrome M Bombardieri, OD Argyropoulou, F Ferro, R Coleby, E Pontarini, ... Clin Exp Rheumatol 38 (4), 3-9, 2020 | 64 | 2020 |
| The CC homozygosis of the− 174G> C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis M Fabris, L Quartuccio, S Lombardi, M Saracco, F Atzeni, A Carletto, ... Autoimmunity reviews 11 (5), 315-320, 2012 | 55 | 2012 |
| Dopamine inhibits the effector functions of activated NK cells via the upregulation of the D5 receptor J Mikulak, L Bozzo, A Roberto, E Pontarini, P Tentorio, K Hudspeth, ... The Journal of Immunology 193 (6), 2792-2800, 2014 | 50 | 2014 |
| B cell depletion with rituximab in the treatment of primary Sjögren's syndrome: what have we learnt? S Grigoriadou, F Chowdhury, E Pontarini, A Tappuni, SJ Bowman, ... Clin Exp Rheumatol 37 (Suppl 118), S217-24, 2019 | 42 | 2019 |
| CXCL13 as biomarker for histological involvement in Sjögren’s syndrome S Colafrancesco, R Priori, CG Smith, A Minniti, V Iannizzotto, E Pipi, ... Rheumatology 59 (1), 165-170, 2020 | 39 | 2020 |
| Transforming growth factor β 869C/T and interleukin 6-174G/C polymorphisms relate to the severity and progression of bone-erosive damage detected by ultrasound in rheumatoid … F Ceccarelli, C Perricone, M Fabris, C Alessandri, A Iagnocco, C Fabro, ... Arthritis research & therapy 13, 1-10, 2011 | 39 | 2011 |
| The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis … M Fabris, L Quartuccio, E Vital, E Pontarini, S Salvin, C Fabro, A Zabotti, ... Arthritis & Rheumatism 65 (1), 88-97, 2013 | 38 | 2013 |
| Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab M Fabris, S De Vita, N Blasone, D Visentini, E Pezzarini, E Pontarini, ... Autoimmunity Highlights 1, 87-94, 2010 | 37 | 2010 |
| Blocking T cell co-stimulation in primary Sjögren's syndrome: rationale, clinical efficacy and modulation of peripheral and salivary gland biomarkers E Pontarini, GM Verstappen, S Grigoriadou, FGM Kroese, H Bootsma, ... Clinical and experimental rheumatology 38 (4), 222-227, 2020 | 34 | 2020 |
